AMENDMENTS

Please incorporate the following amendments to the subject application.

In the Claims:

1-7. (Canceled)

8. (Currently Amended) A method of ~~**modulating**~~ **inhibiting** angiogenesis/vascular development in a host **having a condition associated with unwanted angiogenesis**, said method comprising:

systemically administering to said host an effective amount of a Ca2+/calcineurin/NF-ATc ~~**modulatory**~~ **inhibitory** agent to **inhibit** ~~**modulate**~~ angiogenesis/vascular development in said host~~, said method comprising~~ **having a condition associated with unwanted angiogenesis**.

9. (Original) The method according to Claim 8, wherein said agent is an NF-ATc antagonist.

10. (Original) The method according to Claim 9, wherein said agent inhibits phosphorylation of NF-ATc.

11. (Original) The method according to Claim 10, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.

12-14. (Canceled)

15. (Currently Amended) A method of inhibiting tumor growth in a host **having a neoplastic disease condition**, said method comprising:

systemically administering to said host **having a neoplastic disease condition** an effective amount of a Ca2+/calcineurin/NF-ATc inhibitory agent to inhibit tumor

growth in said host.

16. (Original) The method according to Claim 15, wherein said agent is an NF-ATc antagonist.

17. (Original) The method according to Claim 16, wherein said agent inhibits phosphorylation of NF-ATc.

18. (Original) The method according to Claim 16, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.

19-34. (Canceled)

35. (Previously Presented) The method according to Claim 8, wherein said agent is FK506 or a synthetic mimetic thereof.

36. (Currently Amended) The method according to Claim 8, wherein said agent is ~~rapamaycin~~ **rapamycin** or a synthetic mimetic thereof.

37. (Previously Presented) The method according to Claim 8, wherein said agent is a cyclosporin.

38. (Previously Presented) The method according to Claim 37, wherein said cyclosporin is cyclosporin A.

39. (Previously Presented) The method according to Claim 38, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.

40. (Previously Presented) The method according to Claim 15, wherein said agent is FK506 or a synthetic mimetic thereof.

41. (Currently Amended) The method according to Claim 15, wherein said agent is ~~rapamaycin~~ **rapamycin** or a synthetic mimetic thereof.

42. (Previously Presented) The method according to Claim 15, wherein said agent is a cyclosporin.

43. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is cyclosporin A.

44. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.

45. (Canceled)

46. (Currently Amended) A method of ~~modulating~~ **inhibiting** angiogenesis/vascular development in a host **having a condition associated with unwanted angiogenesis**, said method comprising:

administering to said host an effective amount of a cyclosporin **to inhibit angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis**.

47. (Currently Amended) A method of inhibiting tumor growth in a host **having a neoplastic disease condition**, said method comprising:

administering to said host an effective amount of a cyclosporin **to inhibit tumor growth in said host having a neoplastic disease condition**.